Citation Impact
Citing Papers
A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
2012
Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
2010
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
2015 Standout
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
1999 Standout
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
2007
Placental bed spiral arteries in the hypertensive disorders of pregnancy
1991
A Population-Based Study of Patterns of Care for Ovarian Cancer: Who Is Seen by a Gynecologic Oncologist and Who Is Not?
2002
Randomized Study Comparing Carboplatin/Cyclophosphamide and Cisplatin/Cyclophosphamide as First-Line Treatment in Patients with Stage III/IV Epithelial Ovarian Cancer and Small Volume Disease
1997
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
1991 Standout
A view on drug resistance in cancer
2019 StandoutNature
Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency
2001
Carboplatin with cyclophosphamide in patients with advanced ovarian cancer: an efficacy and quality-adjusted survival analysis
1992
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
2002
Ovarian cancer
2014 Standout
Timing of debulking surgery in advanced ovarian cancer
2008
Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results
2000
Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts
1993
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials
2009 Standout
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
2015 Standout
International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma
2003
Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin
1994
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Nasopharyngeal carcinoma
2019 Standout
Survival of Californian women with epithelial ovarian cancer, 1994–1996: a population-based study
2003
Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
2017 Standout
Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer
2005
A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma
1993
Primary Surgery in Ovarian Cancer: Current Opinions
1995
Informing patients with cancer of ‘new findings’ that may influence their willingness to participate in research studies
2003
Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial
2006
Effectiveness of comprehensive care programs for patients with multiple chronic conditions or frailty: A systematic literature review
2016
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
A Critique of Surgical Cytoreduction in Advanced Ovarian Cancer
2000
Fetal bone marrow as a source of stem cells for in utero or postnatal transplantation
2000
Pre-eclampsia
2005 Standout
Diagnostic open laparoscopy in the management of advanced ovarian cancer
2005
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial
2009
Primary surgery for ovarian cancer
2006
Integrated genomic characterization of endometrial carcinoma
2013 StandoutNature
Cycloplatam: A novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin
1995
Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma
2004
Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: A study of the Grupo de Estudio y Tratamiento Latino‐Americano del cancer
1991
Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
1991
Advanced epithelial ovarian carcinoma: Long-term survival experience at the community hospital
1992
MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue
1998
Hematopoietic Stem-Cell Transplantation for the Treatment of Severe Combined Immunodeficiency
1999
Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type
2010
Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.
1991
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer
1992
Pre-eclampsia
2010 Standout
Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
1992
Frailty: implications for clinical practice and public health
2019 Standout
Cytoreductive surgery for advanced stages of ovarian cancer
2000
The “Great Obstetrical Syndromes” are associated with disorders of deep placentation
2010 Standout
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
2010
Combined Carboplatin plus Ifosfamide and Cisplatin in Patients with Advanced Ovarian Carcinoma. A Phase I–II Study
1998
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis
2006
Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic review
2008
Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer.
1994
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients
1997
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients
1998
Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study
2014
Recent progress in the diagnosis and treatment of ovarian cancer
2011
Cytokine Signaling in 2002
2002 Standout
The Uterine Spiral Arteries In Human Pregnancy: Facts and Controversies
2006 Standout
In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin
1993
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Prognostic stratification of patients with metastatic nasopharyngeal carcinoma using a clinical and biochemical scoring system
2017
Disruption of c-mos causes parthenogenetic development of unfertilized mouse eggs
1994 StandoutNatureNobel
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
New platinum antitumor complexes
1993
Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma
2005
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Cervical cancer
2019 Standout
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Practical methods for incorporating summary time-to-event data into meta-analysis
2007 Standout
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Surgical Staging and Treatment of Early Ovarian Cancer: Long-term Analysis From a Randomized Trial
2010
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Carboplatin versus cisplatin in solid tumors: An analysis of the literature
1998
Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction
2006
High-Dose Platinum versus Standard Dose in Advanced Ovarian Carcinoma: A Randomized Trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)
2000
Cancer of the Ovary
2004 Standout
Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate
2002
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
2008
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
2007
Polysialic Acid, a Glycan with Highly Restricted Expression, Is Found on Human and Murine Leukocytes and Modulates Immune Responses
2008 StandoutNobel
The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer
2005
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Frailty and Multimorbidity: A Systematic Review and Meta-analysis
2018
Granulosa Cell Tumor of the Ovary
2003
Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer
2002
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
2000 StandoutScience
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
2005 Standout
Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries
2016
Adjuvant Treatment for Early Ovarian Cancer: A Randomized Phase III Trial of Intraperitoneal 32P or Intravenous Cyclophosphamide and Cisplatin—A Gynecologic Oncology Group Study
2003
Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease
2016
Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer
2002
Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma
1990
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
2003 Standout
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
2018 Standout
Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells
2005
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer
2004 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Preterm labor: One syndrome, many causes
2014 StandoutScience
Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.
1992
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
Concept of Optimal Surgical Cytoreduction in Advanced Ovarian Cancer: A Brief Critique and a Call for Action
2007
Simultaneous radiation and chemotherapy for advanced carcinoma of the cervix
1987
Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers
2013
Chemical and Biological Studies on a Series of Novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-Diaminocyclohexane)platinum(IV) Carboxylate Complexes
1997
Combined Intraperitoneal and Intravenous Chemotherapy for Women With Optimally Debulked Ovarian Cancer: Results From an Intergroup Phase II Trial
2003
Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.
1999
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
2013 StandoutNobel
Germ Cell Tumors
1992
Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and-resistant human ovarian carcinoma cell lines by amphotericin B
1994
Phase I/II Study Of Concomitant Irradiation and Carboplatin for Locally Advanced Carcinoma of the Uterine Cervix: An Interim Report
1996
Five‐year survival for cisplatin‐based chemotherapy versus single‐agent melphalan in patients with advanced ovarian cancer and optimal debulking surgery
1991
Works of S. Pecorelli being referenced
The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer
1995
Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database
2015
Histological features of uteroplacental vessels in normal and hypertensive patients in relation to birthweight
1989
Adjuvant treatment for early epithelial ovarian cancer: Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)
1995
What have we learned from ICON1 and ACTION?
2003
Randomized Trial in Advanced Ovarian Cancer Comparing Cisplatin and Carboplatin
1989
In-utero transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe combined immunodeficiency (SCIDX1)
1996
Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment
2005
Prognostic factors in advanced epithelial ovarian cancer
1990
Time to face the challenge of multimorbidity. A European perspective from the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS)
2015
Final results of After-6 protocol 1: A phase III trial of observation versus 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT)
2007
Management of early ovarian cancer.
1998
Cisplatin, vinblastine, and bleomycin combination chemotherapy in endodermal sinus tumor of the ovary.
1987
Vincristine, bleomycin, mitomycin C, cisplatin combination chemotherapy as additive treatment to radiotherapy in poor risk patients with squamous cell carcinoma of the uterine cervix.
1985
Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium
2009 Standout
Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial
2003
Cisplatin (P), vinblastine (V), and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa cell tumor of the ovary (GCTO): An eortc gynecology cancer cooperative group study
1989
The Effect of Debulking Surgery After Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer
1995
A phase II study of oral gimatecan (ST1481) in women with progressing or recurring advanced epithelial ovarian, fallopian tube and peritoneal cancers
2006
Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1
2009
Cisplatin, Vinblastine, and Bleomycin Combination Chemotherapy in Metastatic Granulosa Cell Tumor of the Ovary
1986